Jeroen Gerritsen, FSD researcher
Female Sexual Dysfunction (FSD) is a group of disorders containing different subgroups:
Sexual desire disorders
Sexual arousal disorders
Sexual pain disorders (such as dyspareunia and vaginismus).
Most common disorders are Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Arousal Disorder (FSAD). In the latest DSM-5 these disorders have been combined into FSIAD: Female Sexual Interest/Arousal Disorder.
It is believed that there may be a FSD subgroup consisting of women with relatively little interest in sex but no particular negative association with it. However, another group has an explicit negative association possibly due to a history of sexual abuse. Two potential drugs for FSD, Lybridos and Lybrido, have been developed by Emotional Brain, a research company in Almere. They believe that each drug may particularly benefit one FSD subgroup.
In partnership with Emotional Brain, ATIA is evaluating the predictive power of measures of:
Physiological responding (measuring genital blood flow)
Subjective experience (questionnaires)
Motivation (EEG data)
These measures reflect different (sub) domains and most likely interact with each other, but the amount of data and its complexity may become overwhelming. Integrating these data, using advanced reasoning software based on AI technology, could provide a solution. The ATIA reasoning agents are able to trace unseen correlations, inconsistencies and generate new hypotheses which will be tested using actual data.
Research of the underlying mechanisms and tailoring drug intervention will substantially improve drug efficacy on FSD.
An interesting article about Lybrido en Lybridos has been published in The New York Times Magazine on May 26 2013.
Read more here....